Triomics
Triomics is helping cancer centers use their health record data using Generative AI for reducing the manual labor in oncology research and care.
Triomics
Triomics is helping cancer centers use their health record data using Generative AI for reducing the manual labor in oncology research and care.
TL;DR
What they do: Oncology-focused generative AI platform (OncoLLM) that parses unstructured medical records to power clinical-trial matching, registry abstraction, pre-charting, and other oncology workflows
Founded: 2021
Notable customers / deployments: Reported deployments or partnerships with major cancer centers including Memorial Sloan Kettering and Yale Cancer Center
Recent funding: $15M Series A announced May 9, 2024
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Clinical data extraction and workflow automation for oncology (trial matching, registry abstraction, pre-charting).
Founded
2021
Industry
Software Development
Funding Track Record
$15M
Announced May 9, 2024
Recorded as a non-equity assistance round
Investor Signal
“Investors include Lightspeed, Nexus, Y Combinator, General Catalyst, and PharmStars”